Vericel Co. (NASDAQ:VCEL - Get Free Report) CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the transaction, the chief executive officer now directly owns 195,307 shares of the company's stock, valued at $8,708,739.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Dominick Colangelo also recently made the following trade(s):
- On Wednesday, March 13th, Dominick Colangelo sold 17,500 shares of Vericel stock. The stock was sold at an average price of $44.67, for a total value of $781,725.00.
Vericel Price Performance
Shares of Vericel stock opened at $43.74 on Friday. Vericel Co. has a one year low of $29.24 and a one year high of $53.05. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -486.00 and a beta of 1.71. The business has a 50-day simple moving average of $47.58 and a 200 day simple moving average of $40.37.
Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, February 29th. The biotechnology company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.08. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $64.28 million. During the same period in the previous year, the company posted $0.12 EPS. The firm's revenue was up 23.3% compared to the same quarter last year. On average, sell-side analysts expect that Vericel Co. will post 0.09 EPS for the current year.
Analyst Upgrades and Downgrades
The AI stock to buy right now
From StockEarnings | Ad
There are about 350,000 large corporations worldwide.
Can you see the potential for this AI company to grow like crazy?
Click Here to Get the AI Stock Name
Several brokerages recently issued reports on VCEL. HC Wainwright raised their target price on Vericel from $46.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. TheStreet raised Vericel from a "d+" rating to a "c-" rating in a research report on Monday, January 29th. Finally, Truist Financial reissued a "buy" rating and issued a $54.00 price objective on shares of Vericel in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.40.
Read Our Latest Research Report on Vericel
Hedge Funds Weigh In On Vericel
Hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. boosted its stake in Vericel by 54.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 126,383 shares of the biotechnology company's stock valued at $4,236,000 after purchasing an additional 44,507 shares during the last quarter. Legato Capital Management LLC boosted its stake in Vericel by 20.6% during the 4th quarter. Legato Capital Management LLC now owns 10,340 shares of the biotechnology company's stock valued at $368,000 after purchasing an additional 1,765 shares during the last quarter. Federated Hermes Inc. boosted its stake in Vericel by 6.5% during the 3rd quarter. Federated Hermes Inc. now owns 462,467 shares of the biotechnology company's stock valued at $15,502,000 after purchasing an additional 28,262 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in Vericel by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company's stock valued at $83,326,000 after purchasing an additional 109,215 shares during the last quarter. Finally, Citigroup Inc. boosted its stake in Vericel by 19.0% during the 3rd quarter. Citigroup Inc. now owns 71,271 shares of the biotechnology company's stock valued at $2,389,000 after purchasing an additional 11,402 shares during the last quarter.
Vericel Company Profile
(
Get Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
